UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. In the United States, UFT with or without leucovorin has not undergone phase II testing in these malignancies. Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. Secondary objectives include determining response duration, time to disease progression, overall survival, quality of life, and toxicity.

Original languageEnglish (US)
Pages (from-to)124-127
Number of pages4
JournalOncology
Volume11
Issue number9 SUPPL. 10
StatePublished - 1997
Externally publishedYes

Fingerprint

Leucovorin
Pancreatic Neoplasms
Adenocarcinoma
Tegafur
Uracil
Disease Progression
Neoplasms
Japan
Quality of Life
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. / Mani, Sridhar.

In: Oncology, Vol. 11, No. 9 SUPPL. 10, 1997, p. 124-127.

Research output: Contribution to journalArticle

@article{8b3fc62711b7459e94572549a4c0bda7,
title = "UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas",
abstract = "UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. In the United States, UFT with or without leucovorin has not undergone phase II testing in these malignancies. Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. Secondary objectives include determining response duration, time to disease progression, overall survival, quality of life, and toxicity.",
author = "Sridhar Mani",
year = "1997",
language = "English (US)",
volume = "11",
pages = "124--127",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 SUPPL. 10",

}

TY - JOUR

T1 - UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas

AU - Mani, Sridhar

PY - 1997

Y1 - 1997

N2 - UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. In the United States, UFT with or without leucovorin has not undergone phase II testing in these malignancies. Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. Secondary objectives include determining response duration, time to disease progression, overall survival, quality of life, and toxicity.

AB - UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. In the United States, UFT with or without leucovorin has not undergone phase II testing in these malignancies. Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. Secondary objectives include determining response duration, time to disease progression, overall survival, quality of life, and toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0030834050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030834050&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 124

EP - 127

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9 SUPPL. 10

ER -